ATE401066T1 - METHODS FOR TREATING EATING DISORDERS - Google Patents

METHODS FOR TREATING EATING DISORDERS

Info

Publication number
ATE401066T1
ATE401066T1 AT00918073T AT00918073T ATE401066T1 AT E401066 T1 ATE401066 T1 AT E401066T1 AT 00918073 T AT00918073 T AT 00918073T AT 00918073 T AT00918073 T AT 00918073T AT E401066 T1 ATE401066 T1 AT E401066T1
Authority
AT
Austria
Prior art keywords
eating disorders
methods
treating eating
treating
nervosa
Prior art date
Application number
AT00918073T
Other languages
German (de)
Inventor
Carl Mendel
Timothy SEATON
Steve Weinstein
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22418412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE401066(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Application granted granted Critical
Publication of ATE401066T1 publication Critical patent/ATE401066T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A compound of formula Ior a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating eating disorders, such as anorexia nervosa, bulimia nervosa, weight-gain after smoking cessation, snacking or binge eating.
AT00918073T 1999-03-19 2000-03-17 METHODS FOR TREATING EATING DISORDERS ATE401066T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12515099P 1999-03-19 1999-03-19

Publications (1)

Publication Number Publication Date
ATE401066T1 true ATE401066T1 (en) 2008-08-15

Family

ID=22418412

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00918073T ATE401066T1 (en) 1999-03-19 2000-03-17 METHODS FOR TREATING EATING DISORDERS

Country Status (23)

Country Link
US (1) US6365633B1 (en)
EP (1) EP1178789B1 (en)
JP (1) JP2003519087A (en)
KR (1) KR100432825B1 (en)
CN (1) CN1188120C (en)
AT (1) ATE401066T1 (en)
AU (1) AU773188C (en)
BR (1) BR0009026A (en)
CA (1) CA2367666C (en)
CZ (1) CZ20013278A3 (en)
DE (1) DE60039508D1 (en)
ES (1) ES2307501T3 (en)
HK (1) HK1045455B (en)
HU (1) HUP0200495A3 (en)
IL (1) IL145240A (en)
MX (1) MXPA01009404A (en)
NO (1) NO20014479L (en)
NZ (1) NZ514011A (en)
PL (1) PL351963A1 (en)
SK (1) SK12992001A3 (en)
TR (1) TR200102646T2 (en)
WO (1) WO2000054765A1 (en)
ZA (1) ZA200107533B (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006963A1 (en) * 1992-06-23 2002-01-17 Young James W. Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
CA2551037A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
US7572783B2 (en) * 2004-08-13 2009-08-11 Amgen Inc. Substituted benzofused heterocycles
EP2286838A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610580B8 (en) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd piperidine derivative compound
WO2007018248A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
BRPI0614649A2 (en) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc hybrid polypeptides with selectable properties
DE602006017712D1 (en) 2005-08-24 2010-12-02 Banyu Pharma Co Ltd PHENYLPYRIDONDERIVAT
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
US20090203738A1 (en) * 2005-09-22 2009-08-13 Eisai R&D Management Co., Ltd. Pharmaceutical Composition for Treating Bulimia and Depression Arising from Bulimia
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
CA2625416A1 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk Novel benzoxathiin derivative
JP4371164B2 (en) 2005-11-10 2009-11-25 萬有製薬株式会社 Aza-substituted spiro derivatives
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
WO2008047544A1 (en) 2006-09-28 2008-04-24 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
MY154869A (en) 2007-01-16 2015-08-14 Ipintl Llc Composition for treating metabolic syndrome
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2010005345A (en) * 2007-11-14 2010-08-31 Amylin Pharmaceuticals Inc Methods for treating obesity and obesity related diseases and disorders.
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
CA2666036C (en) 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
ES2522968T3 (en) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2301936A1 (en) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
ES2624828T3 (en) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
JPWO2010013595A1 (en) 2008-07-30 2012-01-12 Ｍｓｄ株式会社 5-membered or 5-membered or 6-membered condensed cycloalkylamine derivative
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA025380B1 (en) 2011-02-25 2016-12-30 Мерк Шарп Энд Домэ Корп. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
KR20150036245A (en) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 Antidiabetic tricyclic compounds
RU2015140066A (en) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. ANTI-DIABETIC BICYCLIC COMPOUNDS
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN113121450A (en) 2014-08-29 2021-07-16 Tes制药有限责任公司 Alpha-amino-beta-carboxymuconate semialdehyde decarboxylase inhibitors
BR112019007543A2 (en) 2016-10-14 2019-07-02 Tes Pharma S R L alpha-amino-beta-carboximuconic acid inhibitors semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
AR117122A1 (en) 2018-11-20 2021-07-14 Tes Pharma S R L A-AMINO-b-CARBOXIMUCONIC ACID INHIBITORS SEMIALDEHYDE DECARBOXYLASE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2675573B2 (en) * 1988-03-31 1997-11-12 科研製薬株式会社 Brain function improver
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
EP0977572A1 (en) * 1997-04-24 2000-02-09 Merck Sharp & Dohme Ltd. Use of nk-1 receptor antagonists for treating eating disorders
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
SK10312001A3 (en) * 1999-01-20 2002-03-05 Knoll Pharmaceutical Company Method to aid smoking cessation
PT1158973E (en) * 1999-02-24 2005-07-29 Univ Cincinnati USE OF SULFAMATE DERIVATIVES FOR THE TREATMENT OF DRIVE CONTROL DISTURBLES

Also Published As

Publication number Publication date
JP2003519087A (en) 2003-06-17
TR200102646T2 (en) 2002-08-21
WO2000054765A8 (en) 2002-05-23
EP1178789A4 (en) 2004-02-18
CA2367666C (en) 2008-11-25
HK1045455A1 (en) 2002-11-29
ZA200107533B (en) 2002-12-12
WO2000054765A1 (en) 2000-09-21
EP1178789A1 (en) 2002-02-13
PL351963A1 (en) 2003-07-14
SK12992001A3 (en) 2002-03-05
EP1178789B1 (en) 2008-07-16
HUP0200495A3 (en) 2004-09-28
CN1188120C (en) 2005-02-09
DE60039508D1 (en) 2008-08-28
KR100432825B1 (en) 2004-05-24
HK1045455B (en) 2009-04-09
CA2367666A1 (en) 2000-09-21
CN1365276A (en) 2002-08-21
AU773188B2 (en) 2004-05-20
US6365633B1 (en) 2002-04-02
AU3894700A (en) 2000-10-04
IL145240A0 (en) 2002-06-30
BR0009026A (en) 2003-03-05
AU773188C (en) 2006-01-05
KR20020063107A (en) 2002-08-01
IL145240A (en) 2007-02-11
NO20014479L (en) 2001-11-02
HUP0200495A2 (en) 2002-08-28
CZ20013278A3 (en) 2002-07-17
NO20014479D0 (en) 2001-09-14
NZ514011A (en) 2001-09-28
MXPA01009404A (en) 2004-03-19
ES2307501T3 (en) 2008-12-01

Similar Documents

Publication Publication Date Title
ATE401066T1 (en) METHODS FOR TREATING EATING DISORDERS
ATE324371T1 (en) N-SUBSTITUTED HETEROCYCLIC NONARYL NMDA/NR2B ANTAGONISTS
NO20021328L (en) Pyrazolopyrimidia as therapeutic agents
CZ305838B6 (en) N-(2-arylethyl)benzylamines as 5-HT6 receptor antagonists
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
DK0773943T3 (en) Compounds useful as antiproliferative agents and tannin inhibitors
NO20050666L (en) 2,7-substituted indoles and their use as 5-HT6 modulators
NO980919D0 (en) 8-azabicyclo (3.2.1) oct-2-one derivatives, their preparation and use
TR200201205T2 (en) N-substituted carbamoyloxyalkyl-azolium derivatives.
ATE308522T1 (en) OPIOID RECEPTOR ANTAGONISTS
BRPI0407841A (en) heterocyclic kinase inhibitors
RS20060239A (en) Arylalkylcarbamate derivatives, preparation method thereof and use of same in therapeutics
WO2000056315A8 (en) Treatment of pain
EE200100520A (en) N- (2-phenyl-4-aminobutyl) -1-naphthamides as neurokinin-1 receptor antagonists
DK1169029T3 (en) Use of sibutramine or a derivative thereof for the treatment of sleep disorders
HUP0002709A1 (en) Process for the reduction of 1-substituted -3-hydroxymethyl-4- (4-fluorophenyl)tetrahydropyridines
SE0103795D0 (en) Compounds and method for the treatment of overactive bladder
NO20063299L (en) Synthesis of a polymorph of 4-amino-5-chloro-2-methoxy-N- (1-azabicyclo [3.3.1] non-4-yl) benzamide hydrochloride hydrate
BG105996A (en) Method of treating eating disorders
MXPA01009469A (en) Treatment to lower platelet adhesiveness.
MXPA01009461A (en) Treatment of osteoarthritis.
MXPA01009468A (en) Treatment of pulmonary hypertension.
SE0103668D0 (en) Method for the treatment of overactive leaves
MXPA01009463A (en) Treatment of hiatial hernia.
MXPA01009465A (en) Weight loss after pregnancy.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties